Rok 2015

• The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

  Publikacja

  • E. Augustin
  • A. Skwarska
  • A. Weryszko
  • I. Pelikant-Małecka (dawniej: I. Pelikant)
  • E. Sankowska
  • B. Borowa-Mazgaj

  - ACTA PHARMACOLOGICA SINICA - Rok 2015

  Aim: FMS-like receptor tyrosine kinase (FLT3) is expressed in some normal hematopoietic cell types and plays an important role in the pathogenesis of acute myeloid leukemia (AML). In this study, we examined the effects of triazoloacridinone C-1305, an antitumor compound, on AML cells with different FLT3 status in vitro. Methods: A panel of human leukemic cell lines with different FLT3 status was used, including FLT3 internal tandem...

  Pełny tekst do pobrania w serwisie zewnętrznym